{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:26:21Z","timestamp":1793298381560,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Statin-related skeletal muscle disorders range from benign myalgias \u2013 such as non-specific muscle aches or joint pains without elevated serum creatinine kinase (CK) concentration \u2013 to true myositis with &gt;10-fold elevation of serum CK, to rhabdomyolysis and myoglobinuria. The genetic basis of statin-related muscle disorders is largely unknown. Because mutations in the <jats:italic>COQ2<\/jats:italic> gene are associated with severe inherited myopathy, we hypothesized that common, mild genetic variation in <jats:italic>COQ2<\/jats:italic> would be associated with inter-individual variation in statin intolerance. We studied 133 subjects who developed myopathy on statin monotherapy and 158 matched controls who tolerated statins without incident or complaint.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>\n              <jats:italic>COQ2<\/jats:italic> genotypes, based on two single nucleotide polymorphisms (SNP1 and SNP2) and a 2-SNP haplotype, all showed significant associations with statin intolerance. Specifically, the odds ratios (with 95% confidence intervals) for increased risk of statin intolerance among homozygotes for the rare alleles were 2.42 (0.99 to 5.89), 2.33 (1.13 to 4.81) and 2.58 (1.26 to 5.28) for SNP1 and SNP2 genotypes, and the 2-SNP haplotype, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>These preliminary pharmacogenetic results, if confirmed, are consistent with the idea that statin intolerance which is manifested primarily through muscle symptoms is associated with genomic variation in <jats:italic>COQ2<\/jats:italic> and thus perhaps with the CoQ10 pathway.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1476-511x-6-7","type":"journal-article","created":{"date-parts":[[2007,5,2]],"date-time":"2007-05-02T15:31:06Z","timestamp":1178119866000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":131,"title":["Genetic determinants of statin intolerance"],"prefix":"10.1186","volume":"6","author":[{"given":"Jisun","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R","family":"Ban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke A","family":"Miskie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L","family":"Pollex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Hegele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,3,21]]},"reference":[{"issue":"9493","key":"110_CR1","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet. 2005, 366 (9493): 1267-1278.","journal-title":"Lancet"},{"issue":"13","key":"110_CR2","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1517\/14656566.7.13.1701","volume":"7","author":"MH Davidson","year":"2006","unstructured":"Davidson MH, Robinson JG: Lipid-lowering effects of statins: a comparative review. Expert Opin Pharmacother. 2006, 7 (13): 1701-1714.","journal-title":"Expert Opin Pharmacother"},{"issue":"8A","key":"110_CR3","doi-asserted-by":"publisher","first-page":"6C","DOI":"10.1016\/j.amjcard.2005.12.006","volume":"97","author":"H Bays","year":"2006","unstructured":"Bays H: Statin safety: an overview and assessment of the data--2005. Am J Cardiol. 2006, 97 (8A): 6C-26C.","journal-title":"Am J Cardiol"},{"issue":"5","key":"110_CR4","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.amjmed.2006.02.007","volume":"119","author":"KA Antons","year":"2006","unstructured":"Antons KA, Williams CD, Baker SK, Phillips PS: Clinical perspectives of statin-induced rhabdomyolysis. Am J Med. 2006, 119 (5): 400-409.","journal-title":"Am J Med"},{"issue":"3","key":"110_CR5","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s11883-005-0007-3","volume":"7","author":"AH Maitland-van der Zee","year":"2005","unstructured":"Maitland-van der Zee AH, Boerwinkle E: Pharmacogenetics of response to statins: where do we stand?. Curr Atheroscler Rep. 2005, 7 (3): 204-208.","journal-title":"Curr Atheroscler Rep"},{"issue":"4","key":"110_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2165\/00129784-200404040-00005","volume":"4","author":"A Vermes","year":"2004","unstructured":"Vermes A, Vermes I: Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am J Cardiovasc Drugs. 2004, 4 (4): 247-255.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2","key":"110_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/mus.20567","volume":"34","author":"GD Vladutiu","year":"2006","unstructured":"Vladutiu GD, Simmons Z, Isackson PJ, Tarnopolsky M, Peltier WL, Barboi AC, Sripathi N, Wortmann RL, Phillips PS: Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve. 2006, 34 (2): 153-162.","journal-title":"Muscle Nerve"},{"issue":"46","key":"110_CR8","doi-asserted-by":"publisher","first-page":"35840","DOI":"10.1074\/jbc.M004793200","volume":"275","author":"T Ravid","year":"2000","unstructured":"Ravid T, Doolman R, Avner R, Harats D, Roitelman J: The ubiquitin-proteasome pathway mediates the regulated degradation of mammalian 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 2000, 275 (46): 35840-35847.","journal-title":"J Biol Chem"},{"issue":"2","key":"110_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/01.crd.0000154790.42283.a1","volume":"13","author":"JJ Nawarskas","year":"2005","unstructured":"Nawarskas JJ: HMG-CoA reductase inhibitors and coenzyme Q10. Cardiol Rev. 2005, 13 (2): 76-79.","journal-title":"Cardiol Rev"},{"issue":"5","key":"110_CR10","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/mus.20291","volume":"31","author":"SK Baker","year":"2005","unstructured":"Baker SK: Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve. 2005, 31 (5): 572-580.","journal-title":"Muscle Nerve"},{"issue":"2","key":"110_CR11","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1086\/500092","volume":"78","author":"C Quinzii","year":"2006","unstructured":"Quinzii C, Naini A, Salviati L, Trevisson E, Navas P, Dimauro S, Hirano M: A Mutation in Para-Hydroxybenzoate-Polyprenyl Transferase (COQ2) Causes Primary Coenzyme Q10 Deficiency. Am J Hum Genet. 2006, 78 (2): 345-349.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"110_CR12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.clpt.2006.02.013","volume":"79","author":"R Laaksonen","year":"2006","unstructured":"Laaksonen R: On the mechanisms of statin-induced myopathy. Clin Pharmacol Ther. 2006, 79 (6): 529-531.","journal-title":"Clin Pharmacol Ther"},{"issue":"25","key":"110_CR13","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","volume":"114","author":"A Kashani","year":"2006","unstructured":"Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, Krumholz HM: Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006, 114 (25): 2788-2797.","journal-title":"Circulation"},{"issue":"7","key":"110_CR14","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1161\/01.ATV.0000026801.56080.14","volume":"22","author":"RA Hegele","year":"2002","unstructured":"Hegele RA: SNP judgments and freedom of association. Arterioscler Thromb Vasc Biol. 2002, 22 (7): 1058-1061.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"110_CR15","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0828-282X(06)70310-5","volume":"22","author":"R McPherson","year":"2006","unstructured":"McPherson R, Frohlich J, Fodor G, Genest J, Canadian Cardiovascular S: Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol. 2006, 22 (11): 913-927.","journal-title":"Can J Cardiol"},{"issue":"1","key":"110_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/gepi.1370070114","volume":"7","author":"RA Hegele","year":"1990","unstructured":"Hegele RA, Plaetke R, Lalouel JM: Linkage disequilibrium between DNA markers at the low-density lipoprotein receptor gene. Genet Epidemiol. 1990, 7 (1): 69-81.","journal-title":"Genet Epidemiol"},{"issue":"5","key":"110_CR17","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1086\/379378","volume":"73","author":"M Stephens","year":"2003","unstructured":"Stephens M, Donnelly P: A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet. 2003, 73 (5): 1162-1169.","journal-title":"Am J Hum Genet"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-511X-6-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T23:11:48Z","timestamp":1630451508000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/1476-511X-6-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,21]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["110"],"URL":"https:\/\/doi.org\/10.1186\/1476-511x-6-7","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3,21]]},"assertion":[{"value":"5 February 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"7"}}